Abstract
We herein describe the clinical course of a consecutive series of fulminant hepatic failure patients treated with a molecular adsorbent recirculating system (MARS), a cell-free albumin dialysis technique. From November 2000 to September 2002, seven adult patients ages 22–61 (median, 41), one male (14.2%) and six females (85.7%), affected by fulminant hepatic failure underwent seven courses (one to five sessions each, 6 hr in duration) of extracorporeal support using the MARS technique. Pre- and posttreatment blood glucose, liver function tests, ammonia, arterial lactate, electrolytes, hemodynamic parameters, arterial blood gases, liver histology, Glasgow Coma Scale, and coagulation studies were reviewed. No adverse side effects such as generalized bleeding on noncardiogenic pulmonary edema, often seen during MARS treatment, occurred in the patients included in this study. Six patients (85.7%) are currently alive and well, and one (14.2%) died. Four patients (57%) were successfully bridged (two patients in 1 day and two other patients in 4 days) to liver transplantation, while two (5%) recovered fully without transplantation. All the measured variables stabilized after commencement of the MARS. No differences were noted between the pre- and the post-MARS histology. We conclude that the MARS is a safe, temporary life support mechanism for patients awaiting liver transplantation or recovering from fulminant hepatic failure.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Stange J, Mitzner S, Ramlow W, Gliesche T, Hickstein H, Schmidt R: A new procedure for the removal of protein bound drugs and toxins. ASAIO J 39(3):M621–M625, 1993
Jaregui HO: Cellular component of bioartificial liver support systems. Artif Organs 23(10):889–893, 1999
Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, Berger ED, Lauchart W, Peszynski P, Freytag J, Hickstein H, Loock, J, Löhr JM, Liebe S, Emmrich J, Korten G, Schmidt R: Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 6(3):277–286, 2000
Sorkine P, Ben Abraham R, Szold O, Biderman P, Kidran A, Merchav H, Brill S, Oren R: Role of molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure. Crit Care Med 29(7):1332–1336, 2001
Schmidt LE, Svedensen LB, Sørensen VR, Hansen BA, Larsen FS: Cerebral blood flow velocity increases during a single treatment with molecular adsorbents recirculating system in patients with acute on chronic liver failure. Liver Transpl 7(8):709–712, 2001
Schmidt LE, Sørensen VR, Svedensen LB, Hansen BA, Larsen FS: Hemodynamic changes during a single treatment with the molecular adsorbents recirculating system in patients with acute-on-chronic liver failure. Liver Transpl 7(12):1034–1039, 2001
Doria C, Mandala L, Smith J, Vitale CH, Lauro A, Gruttadauria S, Marino IR, Scotti Foglieni C, Magnone M, Scott VL: Effect of MARS in HCV-related intractable pruritus. Liver Transpl 9(4):437–443, 2003
Doria C, Doyle HR, Mandalà L, Marino IR, Caruana G, Gruttadauria S, Lauro A, Magnone M, Scotti Foglieni C, Lamonaca V, Scott VL: Changes in serum electrolytes during treatment of patients in liver failure with molecular adsorbent recirculating system. Int J Artif Organs 26(10):918–923, 2003
Doria C, Mandalà L, Smith J, Caruana G, Scott VL, Gruttadauria S, Magnone M, Marino IR: Thromboelastography used to assess coagulation during treatment with molecular adsorbent recirculating system. Clin Transplant 18:367–371, 2004
Doria C, Mandalà L, Scott VL, Marino IR, Gruttadauria S, Miraglia R, Vitale CH, Smith J: Noncardiogenic pulmonary edema induced by molecular adsorbent recirculating system. Case report. J Artif Organs 6(4):282–285, 2003
O'Grady JG, Schalm SW, Williams R: Acute liver failure: redefining the syndromes. Lancet 342:273–275, 1993
O'Grady JG, Graeme JMA, Hayllar K, Williams R: Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 97:439-445, 1989
O'Grady JG, Gimson AES, O'Brien CJ, Pucknell A, Hughes RD, Williams R: Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 94:1186–1192, 1988.
Van Thiel DH, Brems J, Nadir A, Idilman R, Colantoni A, Holt D, Edelstein S: Liver transplantation for fulminant hepatic failure. J Gastroenterol 37(Suppl XIII):78–81, 2002
Yamazaki Z, Fujimori Y, Sanjo K, Kojimay Y, Sugiura M, Wada T, Inoue N, Sakai T, Oda T, Kominami N, Fujisaki U, Kataoka K: New artificial liver support system (plasma perfusion detoxification) for hepatic coma. 1978. Ther Apher 4(1):23–25, 2000
Hughes RD, Nicolau N, Langley PG, Ellis AJ, Wendon JA, Williams R: Plasma cytokine levels and coagulation and complement activation during use of the extracorporeal liver assist device in acute liver failure. J Artif Organs 22(10):854–858, 1998
Ting PP, Demetriou AA: Clinical experience with artificial liver support systems. Can J Gastroenterol 14(Suppl)D:79D–84D, 2000
Falkenhagen D, Strobl W, Vogt G, Schrefl A, Linsberger I, Gerner FJ, Schoenhofen M. Fractionated plasma separation and adsorption system: a novel system for blood purification to remove albumin bound substances. J Artif Organs 23(1):81–86, 1999
Bismuth H, Figuerio J, Samuel D: What should we expect from a bioartificial liver in fulminant hepatic failure? J Artif Organs 22(1):26–31, 1998
Jalan R, Williams R: Bio-artificial liver support for acute liver failure: Should we be using it to treat patients? Transplantation 73(2):165–166, 2002
Steiner C, Mitzner S: Experiences with MARS liver support therapy in liver failure: analysis of 176 patients of the international MARS registry. Liver 22(Suppl 2):20–25, 2002
Lee WM: Medical progress: acute liver failure. N Engl J Med 329(25):1862–1872, 1993
McAfee JH, Keeffe EB, Lee RG, Rosch J: Transjugular liver biopsy. Hepatology 15(4):726–732, 1992
Stange J, Mitzner SR, Risler T, Erley CM, Lauchart W, Goehl H, Klammt S, Peszynski P, Freytag J, Hickstein H, Löhr M, Liebe S, Schareck W, Hopt UT, Schmidt R: Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. J Artif Organs 23(4):319–330, 1999
Buchalter S, Crain M, Kreisberg: Regulation of lactate metabolism in vivo. Diabetes Metab Rev 5(4):379–391, 1989
Kreisberg R: Lactate homeostasis and lactic acidosis. Ann Intern Med 92(2, Pt 1):227–237, 1980
Fath JJ, Ascher NL, Konstantinided FN, Bloomer J, Sharp H, Najarian JS, Cerra FB: Metabolism during hepatic transplantation: indicators of allograft function. Surgery 96(4):664–674, 1984
De Gasperi A, Mazza E, Corti A, Zoppi F, Prosperi M, Fantini G, Scaiola A, Colella G, Amici O, Notaro P, Rocchini A, Ceresa F, Roselli E, Grugni MC: Lactate blood levels in the perioperative period of orthotopic liver transplantation. Int J Clin Lab Res 27(2):123–128, 1997
Orii R, Sugawara Y, Hayashida M, Yamada Y, Kubota K, Takayama T, Harihara Y, Makuuchi M, Hanaoka K: Peri-operative blood lactate levels in recipients of living-related liver transplantation. Transplantation 69(10):2124–2127, 2000
Hoofnagle JH, Carithers RL Jr, Shapiro C, Ascher N: Fulminant hepatic failure: summary of a workshop. Hepatology 21(1):240–252, 1995
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Doria, C., Mandalá, L., Scott, V.L. et al. Fulminant Hepatic Failure Bridged to Liver Transplantation with a Molecular Adsorbent Recirculating System: A Single-Center Experience. Dig Dis Sci 51, 47–53 (2006). https://doi.org/10.1007/s10620-006-3115-1
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10620-006-3115-1